Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma

Abstract Conventional immunosuppressants are ineffective for the management of EGPA-related asthma. Tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin (TLSP) that has proven efficacy in several phase 3 studies for the treatment of asthma. We treated with off-label...

Full description

Bibliographic Details
Published in:Respiratory Research
Main Authors: Nina Vincent-Galtié, Quentin Marquant, Emilie Catherinot, Felix Ackermann, Antoine Magnan, Colas Tcherakian, Matthieu Groh
Format: Article
Language:English
Published: BMC 2024-07-01
Subjects:
Eosinophilic granulomatosis with polyangiitis
Vasculitis
Asthma
TSLP
Tezepelumab
Online Access:https://doi.org/10.1186/s12931-024-02888-x

Internet

https://doi.org/10.1186/s12931-024-02888-x

Similar Items